Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17855349
Kou R, Michel T (2007) Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling. J Biol Chem 282, 32719-29 17855349
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine increase
SR59230A racepinefrine inhibit treatment-induced increase
butoxamine racepinefrine no effect upon treatment-induced increase
atenolol racepinefrine no effect upon treatment-induced increase
wortmannin racepinefrine no effect upon treatment-induced increase
U0126 racepinefrine inhibit treatment-induced increase
PP2 racepinefrine no effect upon treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine increase
SR59230A racepinefrine inhibit treatment-induced increase
butoxamine racepinefrine no effect upon treatment-induced increase
atenolol racepinefrine no effect upon treatment-induced increase
wortmannin racepinefrine no effect upon treatment-induced increase
U0126 racepinefrine inhibit treatment-induced increase
PP2 racepinefrine no effect upon treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine increase
SR59230A racepinefrine inhibit treatment-induced increase
butoxamine racepinefrine no effect upon treatment-induced increase
atenolol racepinefrine no effect upon treatment-induced increase
wortmannin racepinefrine no effect upon treatment-induced increase
U0126 racepinefrine inhibit treatment-induced increase
PP2 racepinefrine no effect upon treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine increase
SR59230A racepinefrine inhibit treatment-induced increase
butoxamine racepinefrine no effect upon treatment-induced increase
atenolol racepinefrine no effect upon treatment-induced increase
wortmannin racepinefrine no effect upon treatment-induced increase
U0126 racepinefrine inhibit treatment-induced increase
PP2 racepinefrine no effect upon treatment-induced increase

S157-p - VASP (human)
Modsite: EHIERRVsNAGGPPA SwissProt Entrez-Gene
Orthologous residues
VASP (human): S157‑p, VASP (mouse): S153‑p, VASP (rat): S154‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine increase
SR59230A racepinefrine inhibit treatment-induced increase
butoxamine racepinefrine no effect upon treatment-induced increase
atenolol racepinefrine no effect upon treatment-induced increase
wortmannin racepinefrine no effect upon treatment-induced increase
U0126 racepinefrine no effect upon treatment-induced increase
PP2 racepinefrine no effect upon treatment-induced increase
racepinefrine RAC1 (human) increase RAC1 siRNA inhibits increase
racepinefrine PKACA (cow) increase PKACA siRNA inhibits increase

S473-p - Akt1 (cow)
Modsite: RPHFPQFsYSASATA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine increase
wortmannin racepinefrine inhibit treatment-induced increase
U0126 racepinefrine no effect upon treatment-induced increase
PP2 racepinefrine inhibit treatment-induced increase
racepinefrine RAC1 (human) increase RAC1 siRNA inhibits increase
racepinefrine PKACA (cow) increase PKACA siRNA inhibits increase

S116-p - eNOS (cow)
Modsite: RKLQTRPsPGPPPAE SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S114‑p, eNOS (mouse): T113‑p, eNOS (rat): T113‑p, eNOS (rabbit): T120‑p, eNOS (pig): S116‑p, eNOS (cow): S116‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine decrease
SR59230A racepinefrine inhibit treatment-induced decrease
butoxamine racepinefrine no effect upon treatment-induced decrease
atenolol racepinefrine no effect upon treatment-induced decrease
wortmannin racepinefrine no effect upon treatment-induced decrease
U0126 racepinefrine no effect upon treatment-induced decrease
PP2 racepinefrine no effect upon treatment-induced decrease
RAC1 (human) increase RAC1 siRNA decreases

T497-p - eNOS (cow)
Modsite: AGITRKktFKEVANA SwissProt Entrez-Gene
Orthologous residues
eNOS (human): T495‑p, eNOS (mouse): T494‑p, eNOS (rat): T494‑p, eNOS (rabbit): T501‑p, eNOS (pig): T497‑p, eNOS (cow): T497‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine decrease
SR59230A racepinefrine inhibit treatment-induced decrease
butoxamine racepinefrine no effect upon treatment-induced decrease
atenolol racepinefrine no effect upon treatment-induced decrease
wortmannin racepinefrine no effect upon treatment-induced decrease
U0126 racepinefrine no effect upon treatment-induced decrease
PP2 racepinefrine no effect upon treatment-induced decrease
RAC1 (human) increase RAC1 siRNA decreases

S1179-p - eNOS (cow)
Modsite: TSRIRtQsFsLQERH SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine increase
SR59230A racepinefrine inhibit treatment-induced increase
butoxamine racepinefrine no effect upon treatment-induced increase
atenolol racepinefrine no effect upon treatment-induced increase
wortmannin racepinefrine no effect upon treatment-induced increase
U0126 racepinefrine no effect upon treatment-induced increase
PP2 racepinefrine inhibit treatment-induced increase
racepinefrine RAC1 (human) increase RAC1 siRNA inhibits increase